JP2022189853A5 - - Google Patents

Download PDF

Info

Publication number
JP2022189853A5
JP2022189853A5 JP2022161777A JP2022161777A JP2022189853A5 JP 2022189853 A5 JP2022189853 A5 JP 2022189853A5 JP 2022161777 A JP2022161777 A JP 2022161777A JP 2022161777 A JP2022161777 A JP 2022161777A JP 2022189853 A5 JP2022189853 A5 JP 2022189853A5
Authority
JP
Japan
Prior art keywords
pyrrolo
methyl
fluoro
pyridin
isopropyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2022161777A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022189853A (ja
Filing date
Publication date
Priority claimed from JP2019514787A external-priority patent/JP2019529421A/ja
Application filed filed Critical
Publication of JP2022189853A publication Critical patent/JP2022189853A/ja
Publication of JP2022189853A5 publication Critical patent/JP2022189853A5/ja
Priority to JP2024195965A priority Critical patent/JP2025022910A/ja
Pending legal-status Critical Current

Links

JP2022161777A 2016-09-16 2022-10-06 menin-MLL相互作用の阻害剤 Pending JP2022189853A (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2024195965A JP2025022910A (ja) 2016-09-16 2024-11-08 menin-MLL相互作用の阻害剤

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662395618P 2016-09-16 2016-09-16
US62/395,618 2016-09-16
JP2019514787A JP2019529421A (ja) 2016-09-16 2017-09-15 menin−MLL相互作用の阻害剤

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
JP2019514787A Division JP2019529421A (ja) 2016-09-16 2017-09-15 menin−MLL相互作用の阻害剤

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2024195965A Division JP2025022910A (ja) 2016-09-16 2024-11-08 menin-MLL相互作用の阻害剤

Publications (2)

Publication Number Publication Date
JP2022189853A JP2022189853A (ja) 2022-12-22
JP2022189853A5 true JP2022189853A5 (cg-RX-API-DMAC7.html) 2023-06-22

Family

ID=59966892

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2019514787A Withdrawn JP2019529421A (ja) 2016-09-16 2017-09-15 menin−MLL相互作用の阻害剤
JP2022161777A Pending JP2022189853A (ja) 2016-09-16 2022-10-06 menin-MLL相互作用の阻害剤
JP2024195965A Pending JP2025022910A (ja) 2016-09-16 2024-11-08 menin-MLL相互作用の阻害剤

Family Applications Before (1)

Application Number Title Priority Date Filing Date
JP2019514787A Withdrawn JP2019529421A (ja) 2016-09-16 2017-09-15 menin−MLL相互作用の阻害剤

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2024195965A Pending JP2025022910A (ja) 2016-09-16 2024-11-08 menin-MLL相互作用の阻害剤

Country Status (15)

Country Link
US (3) US10899758B2 (cg-RX-API-DMAC7.html)
EP (2) EP3512850B1 (cg-RX-API-DMAC7.html)
JP (3) JP2019529421A (cg-RX-API-DMAC7.html)
KR (1) KR102536029B1 (cg-RX-API-DMAC7.html)
CN (3) CN118359610A (cg-RX-API-DMAC7.html)
AR (1) AR109658A1 (cg-RX-API-DMAC7.html)
AU (1) AU2017326006B2 (cg-RX-API-DMAC7.html)
DK (1) DK3512850T3 (cg-RX-API-DMAC7.html)
ES (1) ES2948949T3 (cg-RX-API-DMAC7.html)
FI (1) FI3512850T3 (cg-RX-API-DMAC7.html)
IL (2) IL295972A (cg-RX-API-DMAC7.html)
MX (2) MX2019003091A (cg-RX-API-DMAC7.html)
PL (1) PL3512850T3 (cg-RX-API-DMAC7.html)
TW (1) TWI757340B (cg-RX-API-DMAC7.html)
WO (1) WO2018053267A1 (cg-RX-API-DMAC7.html)

Families Citing this family (53)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
USRE49687E1 (en) 2014-09-09 2023-10-10 The Regents Of The University Of Michigan Thienopyrimidine and thienopyridine compounds and methods of use thereof
WO2016197027A1 (en) 2015-06-04 2016-12-08 Kura Oncology, Inc. Methods and compositions for inhibiting the interaction of menin with mll proteins
TWI703150B (zh) 2015-06-04 2020-09-01 美商庫拉腫瘤技術股份有限公司 用於抑制menin及mll蛋白之交互作用的方法及組合物
AU2017212572A1 (en) 2016-01-26 2018-08-23 Memorial Sloan-Kettering Cancer Center Targeting chromatin regulators inhibits leukemogenic gene expression in NPM1 mutant leukemia
WO2017161028A1 (en) 2016-03-16 2017-09-21 Kura Oncology, Inc. Substituted inhibitors of menin-mll and methods of use
US10752639B2 (en) 2016-03-16 2020-08-25 Kura Oncology, Inc. Bridged bicyclic inhibitors of menin-MLL and methods of use
CN109415337B (zh) 2016-05-02 2022-01-18 密执安大学评议会 作为多发性内分泌腺瘤蛋白抑制剂的哌啶
ES2831084T3 (es) 2016-06-10 2021-06-07 Vitae Pharmaceuticals Inc Inhibidores de la interacción menina-MLL
AU2017326487B2 (en) 2016-09-14 2021-08-05 Janssen Pharmaceutica Nv Spiro bicyclic inhibitors of menin-MLL interaction
US12084462B2 (en) 2016-09-14 2024-09-10 Janssen Pharmaceutica Nv Spiro bicyclic inhibitors of menin-MLL interaction
TWI753016B (zh) 2016-09-14 2022-01-21 比利時商健生藥品公司 Menin-mll相互作用之稠合二環抑制劑
CN118359610A (zh) * 2016-09-16 2024-07-19 生命医药有限责任公司 Menin-mll相互作用的抑制剂
KR102513564B1 (ko) 2016-12-15 2023-03-22 얀센 파마슈티카 엔.브이. 메닌-mll 상호작용의 아제판 억제제
CN110691779B (zh) 2017-03-24 2023-10-10 库拉肿瘤学公司 治疗血液系统恶性肿瘤和尤因肉瘤的方法
EP3600313A4 (en) 2017-03-31 2020-09-23 The Regents of The University of Michigan PIPERIDINES AS COVALENT MENINE INHIBITORS
US11542248B2 (en) 2017-06-08 2023-01-03 Kura Oncology, Inc. Methods and compositions for inhibiting the interaction of menin with MLL proteins
TW201920170A (zh) 2017-09-20 2019-06-01 美商庫拉腫瘤技術股份有限公司 經取代之menin-mll 抑制劑及使用方法
JP7307729B2 (ja) 2017-12-20 2023-07-12 ヤンセン ファーマシューティカ エヌ.ベー. メニン-mll相互作用のエキソ-アザスピロ阻害剤
US11396517B1 (en) 2017-12-20 2022-07-26 Janssen Pharmaceutica Nv Exo-aza spiro inhibitors of menin-MLL interaction
US11447484B2 (en) * 2018-01-26 2022-09-20 Shionogi & Co., Ltd. Cyclic compound having dopamine D3 receptor antagonistic effect
CN112105621B (zh) 2018-03-30 2024-02-20 住友制药株式会社 光学活性桥型环状仲胺衍生物
TWI815954B (zh) 2018-08-27 2023-09-21 日商住友製藥股份有限公司 光學活性氮雜雙環衍生物
DK3808747T3 (da) * 2018-09-13 2025-02-03 Kissei Pharmaceutical Imidazopyridinon-forbindelse
CA3116141C (en) 2018-12-06 2023-09-05 Daiichi Sankyo Company, Limited Cycloalkane-1,3-diamine derivative
CN114981270B (zh) * 2019-09-20 2024-10-18 诺华公司 Mll1抑制剂和抗癌剂
US12559487B2 (en) * 2019-09-27 2026-02-24 Sumitomo Pharma Co., Ltd. Crosslinked optically active secondary amine derivative
UY38988A (es) 2019-12-19 2021-06-30 Janssen Pharmaceutica Nv Derivados espiráncos sustituidos de cadena lineal
WO2021138540A1 (en) 2020-01-03 2021-07-08 Berg Llc Polycyclic amides as ube2k modulators for treating cancer
CN111297863B (zh) * 2020-03-30 2021-06-25 四川大学华西医院 menin-MLL抑制剂在制备治疗子宫内膜癌的药物中的应用
IL297039A (en) 2020-04-07 2022-12-01 Syndax Pharmaceuticals Inc Combinations of menin inhibitors and cyp3a4 inhibitors and methods of use thereof
AR122159A1 (es) * 2020-05-28 2022-08-17 Novartis Ag Inhibidores de mll1 y agentes antineoplásicos
UY39569A (es) 2020-12-17 2022-07-29 Astrazeneca Ab N-(2-(4-cianotiazolidin-3-il)-2-oxoetil)- quinolin-4-carboxamidas
BR112023021040A2 (pt) 2021-05-08 2024-02-06 Janssen Pharmaceutica Nv Derivados espiro substituídos
EP4334310A1 (en) 2021-05-08 2024-03-13 JANSSEN Pharmaceutica NV Substituted spiro derivatives
AR125866A1 (es) 2021-05-14 2023-08-23 Syndax Pharmaceuticals Inc Inhibidores de la interacción de menina-mll
CA3218479A1 (en) * 2021-06-01 2022-12-08 Wei Cai Substituted phenyl-1h-pyrrolo[2, 3-c]pyridine derivatives
WO2022253289A1 (en) 2021-06-03 2022-12-08 Janssen Pharmaceutica Nv Pyridazines or 1,2,4-triazines substituted by spirocyclic amines
AU2022292697A1 (en) 2021-06-17 2024-02-01 Janssen Pharmaceutica Nv (r)-n-ethyl-5-fluoro-n-isopropyl-2-((5-(2-(6-((2-methoxyethyl)(methyl)amino)-2-methylhexan-3-yl)-2,6-diazaspiro[3.4]octan-6-yl)-1,2,4-triazin-6-yl)oxy)benzamide besylate salt for the treatment of diseases such as cancer
CN116903609A (zh) * 2021-11-05 2023-10-20 上海优理惠生医药有限公司 一种化合物、包含其的药物组合物及其应用
US20250000799A1 (en) * 2021-11-11 2025-01-02 V-Ensure Pharma Technologies Private Limited Reconstitutable, Single Use Antidiabetic Compositions
JP2025513798A (ja) * 2022-04-08 2025-04-30 ヤンセン ファーマシューティカ エヌ.ベー. メニン/mll相互作用の阻害剤の結晶質形態
US20260151399A1 (en) 2022-11-24 2026-06-04 Oryzon Genomics, S.A. Combinations of lsd1 inhibitors and menin inhibitors for treating cancer
JP2025540762A (ja) * 2022-11-30 2025-12-16 ヤンセン ファーマシューティカ エヌ.ベー. メニン-mll阻害剤及びbcl-2阻害剤を含む組み合わせ
EP4626885A1 (en) * 2022-11-30 2025-10-08 Janssen Pharmaceutica NV Cyclobutyl substituted bicyclic compounds
JP2025540759A (ja) * 2022-11-30 2025-12-16 ヤンセン ファーマシューティカ エヌ.ベー. メニン-mll阻害剤及び少なくとも1つの他の治療剤を含む組み合わせ
WO2024114658A1 (en) * 2022-11-30 2024-06-06 Janssen Pharmaceutica Nv Substituted 1-phenyl-3, 4-dihydropyrido [3, 4-d] pyrimidin-2-one derivatives
AR132185A1 (es) * 2023-03-24 2025-06-04 Acerta Pharma Bv COMPUESTOS DE 1-H-PIRROLO[2,3-c]PIRIDINA
CN121969626A (zh) * 2023-09-27 2026-05-01 苏州必扬医药科技有限公司 一种Menin-MLL相互作用抑制剂及其制备方法和应用
KR20260115654A (ko) * 2023-12-04 2026-07-24 쇼우야오 홀딩스 (베이징) 코., 엘티디. 치환된 다환 화합물
US12605394B2 (en) 2024-07-25 2026-04-21 Visionary Assets, Llc Compositions containing cannabinoid nanoparticles
US12667578B2 (en) 2024-07-25 2026-06-30 Visionary Assets, Llc Cryogenic process for making cannabinoid nanoparticles and compositions made thereby
WO2026062248A1 (en) * 2024-09-20 2026-03-26 Acerta Pharma B.V. Solid-state forms of ((s)-2-(3-(1-(5,5-dimethylpyrrolidine-2-carbonyl)piperidine-4-carbonyl)-2-methyl-1h-pyrrolo[2,3-c]-pyridin-1-yl)-5-fluoro-n,n-diisopropylbenzamide salts
WO2026158355A1 (zh) * 2025-01-22 2026-07-30 首药控股(北京)股份有限公司 取代的多环化合物

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CZ2001959A3 (cs) 1998-09-18 2001-12-12 Basf Aktiengesellschaft 4-Aminopyrrolopyrimidiny jako inhibitory kinasy
EP1874769B1 (de) 2005-04-25 2011-09-14 Merck Patent GmbH Neuartige aza-heterozyklen als kinase-inhibitoren
WO2010066629A2 (en) 2008-12-09 2010-06-17 F. Hoffmann-La Roche Ag Novel azaindoles
GB201004311D0 (en) * 2010-03-15 2010-04-28 Proximagen Ltd New enzyme inhibitor compounds
US8940725B2 (en) * 2010-05-31 2015-01-27 Ono Pharmaceutical Co., Ltd. Purinone derivative
BR112014007788A2 (pt) 2011-10-03 2017-04-18 Univ North Carolina Chapel Hill compostos de pirrolopirimidina para tratamento do câncer
US8377946B1 (en) * 2011-12-30 2013-02-19 Pharmacyclics, Inc. Pyrazolo[3,4-d]pyrimidine and pyrrolo[2,3-d]pyrimidine compounds as kinase inhibitors
JP6327713B2 (ja) * 2012-07-27 2018-05-23 国立研究開発法人理化学研究所 急性骨髄性白血病の治療又は再発抑制剤
KR20150084923A (ko) 2012-11-15 2015-07-22 파마시클릭스, 인코포레이티드 키나제 억제제로서의 피롤로피리미딘 화합물
CA2915163A1 (en) * 2013-06-12 2014-12-18 Proximagen Limited New therapeutic uses of enzyme inhibitors
WO2015058084A1 (en) * 2013-10-18 2015-04-23 Medivation Technologies, Inc. Heterocyclic compounds and methods of use
US10278979B2 (en) * 2015-03-11 2019-05-07 Riken Therapeutic agent for intractable leukemia
CN118359610A (zh) * 2016-09-16 2024-07-19 生命医药有限责任公司 Menin-mll相互作用的抑制剂

Similar Documents

Publication Publication Date Title
AU2023203504B2 (en) Substituted 4-aminoisoindoline-1,3-dione compounds and their use for treating lymphoma
JP2019517548A5 (cg-RX-API-DMAC7.html)
JP2024532733A (ja) 複素環式化合物及び使用方法
JP2025533831A (ja) Kras g12c変異タンパク質のテザー型複素環式阻害剤及びその使用
RU2013155456A (ru) Соединения пирролидинилмочевины и пирролидинилтиомочевины как ингибиторы киназы trka
JP2012501312A5 (cg-RX-API-DMAC7.html)
JP2019535689A5 (cg-RX-API-DMAC7.html)
JP2022533120A5 (cg-RX-API-DMAC7.html)
RU2014154397A (ru) Соединения тетрагидропиразолопиримидина
RU2018126774A (ru) Ингибиторы менин-mll взаимодействия
RU2011116447A (ru) Модуляторы амилоида бета
US12350265B2 (en) Pharmaceutical composition for treating acute myeloid leukemia, containing FLT3 inhibitor and chemotherapeutic agents
ES2864950T9 (es) Compuestos de 1-ciano-pirrolidina como inhibidores de USP30
JP2014521711A5 (cg-RX-API-DMAC7.html)
JP2014527959A5 (cg-RX-API-DMAC7.html)
HRP20120174T1 (hr) Derivat policikličnog cinamida
JP2013523819A5 (cg-RX-API-DMAC7.html)
RU2012113593A (ru) Ингибиторы jak
HUP9904434A2 (hu) Pirazolo[4,3-d]pirimidinon-, kinazolinon-, purinon- és pirido[3,2-d]pirimidinon-származékok alkalmazása nitrát-indukált tolerancia kezelésére szolgáló gyógyszerkészítmények előállítására
WO2013173506A2 (en) Method of treating muscular degradation
CN118556059A (zh) 用于治疗癌症的杂环化合物
JP2018501209A5 (cg-RX-API-DMAC7.html)
JP7681116B6 (ja) カルボニル置換ジアザスピロ化合物及びその使用
CA2905530A1 (en) Pyrrolo[2,3-b]pyridine cdk9 kinase inhibitors
JP2023052514A (ja) チアジアゾールirak4阻害剤